(Johnson & Johnson) Johnson & Johnson posted total sales of $23.3 billion in the third quarter of 2021, up 10.7% from the prior year.
US sales amounted to $11.963 billion, up 7.9% year over year. International sales were $11.375 billion, up 13.8% over the same period.
The consumer health segment sales grew by 5.3% year over year to $3.7 billion. Pharmaceutical sales rose by 13.8% to 12.994 billion, as medical devices posted gains of 8.0% to 6.644 billion.
The company’s net earnings were $3.667 billion or $1.37 earnings per share, up 3.2% and 3.0%, respectively, from the prior year.
J&J now projects FY21 sales of $91.6 billion to $92.1 billion, up 10.9%-11.5% from the prior year. EPS is expected in the range of $9.77-$9.82, up 21.7%-22.3% from the prior year.
JNJ: NYSE is up +2.43%.
